Ocular adverse events (combined safety and efficacy arms)
| Standard formulation | New formulation | |||
|---|---|---|---|---|
| Efficacy (n=15) | Safety (n=20) | Efficacy (n=15) | Safety (n=20) | |
| Events persisting in excess of 1 hour | ||||
| Redness | 3 | 4 | 3 | 6 |
| Itching | 1 | 0 | 1 | 1 |
| Irritation | 1 | 0 | 1 | 2 |
| Pain | 0 | 0 | 0 | 0 |
| Blurring | 0 | 0 | 0 | 0 |
| Burning | 1 | 0 | 1 | 0 |
| Discomfort | 2 | 0 | 2 | 0 |
| Severe pain | 0 | 0 | 1 | 0 |
| Total eyes with at least one event | 4 (27%) | 4 (20%) | 4 (27%) | 6 (30%) |
| Number of eyes with any event persisting less than 1 hour | 7 (47%) | 5 (25%) | 10 (67%) | 15 (75%) |
| Total eyes with at least one event of any duration | 8 (53%) | 6 (30%) | 11 (73%) | 15 (75%) |